Trial Profile
Multinational platform trial of RHB-107 for COVID-19 outpatients
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2023
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 04 Jan 2023 New trial record
- 03 Jan 2023 According to a RedHill Biopharma media release, Advanced discussions are ongoing regarding inclusion of once-daily oral RHB-107 in this trial.